**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | ASH VPS EX-US | **Project Code** | PI4VPO108 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Chelsey/Briana B |
| **Compliance** | Briana Devaser | **Editor** | Heather/Christi |

**Launch Date/Internal Launch Date:**

**Friday, December 5 or Monday, December 8**

**Project Type**

Video

Downloadable Slides

Other:

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

Oncology Guru

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
Content Available by:

**CME?**

Yes

No

**Webcast/PDS URL:**

**www.primeoncology.org/sanfrancisco\_vp\_exus**

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title: ASH Hematology Posters**

**Listing Page**

**[Insert small VPS EX-US Graphic to the left]**

**[TITLE]**

Virtual Poster Session: Clinical Implications and Optimal Application of Emerging Data From   
the 2014 Annual Hematology Meeting in San Francisco

**[DATE** | **LOCATION]**

December 2014| San Francisco, California

**Landing Page**

**[Insert VPS EX-US Graphic header]**

**LEFT SIDE**

**[Insert Text below]**

Virtual Poster Session: Clinical Implications and Optimal Application of Emerging Data From   
the 2014 Annual Hematology Meeting in San Francisco

**Activity Features**

**[Insert icon]** Interactive Presentation

**[Insert icon]** Downloadable Slides

**RIGHT SIDE**

**ACTIVITY OVERVIEW**

View abstract presentations and downloadable slides from the 2014 Annual Hematology Meeting in San Francisco

**BOTTOM MIDDLE**

**[Insert List of Disease Type Tabs…as many as needed]**

* **All**
* **CML**
* **Lymphoma**
* **MM**
* **MPN**

**[Tab-CML]**

**Chronic Myeloid Leukemia**

[Insert Screen Shot] **Abstract #152:** Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056)

*Presented by: Jorge Cortes, MD*

[Button to the right of the abstract listing] View

**[Insert divider line]**

[Insert Screen Shot] **Abstract #519:** EPIC: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

*Presented by: Jeffrey Lipton, MD, PhD, FRCPC*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #4532:** Deep Molecular Response to Nilotinib as First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party

*Presented by: Fausto Castagnetti, MD, PhD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #4541:** Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

*Presented by: Giuseppe Saglio, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

**[Tab-Lymphoma]**

**Lymphoma**

[Insert Screen Shot] **Abstract #501:** Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

*Presented by: Robert Chen, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #626:** Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study

*Presented by: Marek Trneny MD, PhD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #673:** The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

*Presented by: Craig Moskowitz, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #TBD:** TBD

*Presented by: TBD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

**[Tab-MM]**

**Multiple Myeloma**

[Insert Screen Shot] **Abstract #32:** Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients With Relapsed and Refractory Myeloma: A Multiple Myeloma Research

*Presented by: Jonathan Kaufman, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #33: Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy With Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma**

*Presented by: Jatin Shah, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #79:** Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) With Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study

*Presented by: A. Keith Stewart, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #82:** Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

*Presented by: Shaji Kumar, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #175:** Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study

*Presented by: Antonio Palumbo, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #198:** Impact of Autologous Transplantation vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials

*Presented by: Francesca Gay, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #4742:** Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

*Presented by: Jesus San Miguel, MD, PhD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

**[Tab-MPN]**

**Myeloproliferative Neoplasms**

[Insert Screen Shot] **Abstract #320:** Reduced Intensity vs. Standard Conditioning Followed by Allogeneic Stem Cell Transplantation for Patients With MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)

*Presented by: Nicolaus Kröger, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #405:** Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project

*Presented by: Alessandro Vannucchi, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #709: Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results**

*Presented by: Ruben Mesa, MD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #711:** Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients With Intermediate or High-Risk Myelofibrosis

*Presented by: Jean-Jacques Kiladjian, MD, PhD*

**[Button to the right of the abstract listing] View**

**[Insert divider line]**

[Insert Screen Shot] **Abstract #1860:** The Prognostic Impact of the Mutational Profile in Patients With Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib

*Presented by: Elias Jabbour, MD*

**[Button to the right of the abstract listing] View**

**Player Page (CML-Cortes)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #152:** Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056)

*Presented by: Jorge Cortes, MD*

**Click here to view abstract [**[**https://ash.confex.com/ash/2014/webprogram/Paper68183.html**](https://ash.confex.com/ash/2014/webprogram/Paper68183.html)**]**

**FEATURED EXPERTS**

**Jorge Cortes, MD**

The University of Texas

MD Anderson Cancer Center

Houston, Texas, United States

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (CML-Lipton)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #519:** EPIC: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

*Presented by: Jeffrey Lipton, MD, PhD, FRCPC*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper70542.html]**

**FEATURED EXPERTS**

**Jeffrey Lipton, MD, PhD, FRCPC**

Princess Margaret Cancer Centre

University of Toronto

Toronto, Ontario, Canada

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (CML-Castagnetti)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #4532:** Deep Molecular Response to Nilotinib as First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party

*Presented by: Fausto Castagnetti, MD, PhD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper72851.html]**

**FEATURED EXPERTS**

**Fausto Castagnetti, MD, PhD**

Bologna University School of Medicine

Bologna, Italy

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (CML-TBD)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #\_\_\_:** TBD

*Presented by: TBD*

**Click here to view abstract [http://TBD]**

**FEATURED EXPERTS**

TBD

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (Lymphoma-Chen)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #501:**  Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

*Presented by: Robert Chen, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper68035.html]**

**FEATURED EXPERTS**

**Robert Chen, MD**

City of Hope

Duarte, California, United States

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (Lymphoma-Trneny)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #626:** Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study

*Presented by: Marek Trneny MD, PhD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper69212.html]**

**FEATURED EXPERTS**

**Marek Trneny MD, PhD**

Charles University Hospital

Prague, Czech Republic

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (Lymphoma-Moskowitz)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #673:** The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

*Presented by: Craig Moskowitz, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper67040.html]**

**FEATURED EXPERTS**

**Craig Moskowitz, MD**

Memorial Sloan Kettering Cancer Center

New York, New York, United States

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (Lymphoma-TBD)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract**

*Presented by: MD*

**Click here to view abstract [http://]**

**FEATURED EXPERTS**

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MM-Kaufman)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #32:** Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients With Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

*Presented by: Jonathan Kaufman, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper70568.html**

**FEATURED EXPERTS**

**Jonathan Kaufman, MD**

Winship Cancer Institute

Emory University

Atlanta, Georgia, United States

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MM-Shah)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #33:** Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy With Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

*Presented by: Jatin Shah, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper76502.html]**

**FEATURED EXPERTS**

**Jatin Shah, MD**

The University of Texas

MD Anderson Cancer Center

Houston, Texas, United States

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MM-Stewart)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #79:** Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) With Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study

*Presented by: A. Keith Stewart, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper70771.html]**

**FEATURED EXPERTS**

**A. Keith Stewart, MD**

Mayo Clinic

Scottsdale, Arizona, United States

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MM-Kumar)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #82:** Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

*Presented by: Shaji Kumar, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper69951.html]**

**FEATURED EXPERTS**

**Shaji Kumar, MD**

Mayo Clinic

Rochester, Minnesota, United States

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MM-Palumbo)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #175:** Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study

*Presented by: Antonio Palumbo, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper68244.html]**

**FEATURED EXPERTS**

**Antonio Palumbo, MD**

University of Torino

Torino, Italy

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MM-Gay)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #198:** Impact of Autologous Transplantation vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials

*Presented by: Francesca Gay, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper68373.html]**

**FEATURED EXPERTS**

**Francesca Gay, MD**

University of Torino

Torino, Italy

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MM-San Miguel)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #4742:** Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

*Presented by: Jesus San Miguel, MD, PhD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper69254.html]**

**FEATURED EXPERTS**

**Jesus San Miguel, MD, PhD**

Universidad de Navarra

Pamplona, Spain

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MPN-** **Kröger)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #320:** Reduced Intensity vs. Standard Conditioning Followed by Allogeneic Stem Cell Transplantation for Patients With MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)

*Presented by: Nicolaus Kröger, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper72696.html]**

**FEATURED EXPERTS**

**Nicolaus Kröger, MD**

University Medical Center Hamburg-Eppendorf

Hamburg, Germany

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MPN-Vannucchi)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #405:** Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project

*Presented by: Alessandro Vannucchi, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper70459.html]**

**FEATURED EXPERTS**

**Alessandro Vannucchi, MD**

University of Florence

Florence, Italy

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MPN-Mesa)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #709:** Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

*Presented with: Ruben Mesa, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper69746.html]**

**FEATURED EXPERTS**

**Ruben Mesa, MD**

Mayo Clinic Cancer Center

Scottsdale, Arizona, United States

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MPN-Kiladjian)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #711:** Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients With Intermediate or High-Risk Myelofibrosis

*Presented by: Jean-Jacques Kiladjian, MD, PhD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper66844.html]**

**FEATURED EXPERTS**

**Jean-Jacques Kiladjian, MD, PhD**

Hôpital Saint-Louis & Université Paris Diderot

Paris, France

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.

**Player Page (MPN-Niederwieser)**

**[Insert VPS ex-US Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Buttons-Downloadable Slides and Evaluate This Activity]**

**ACTIVITY OVERVIEW**

**Abstract #1860:** The Prognostic Impact of the Mutational Profile in Patients With Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib

*Presented by: Dietger Niederwieser, MD*

**Click here to view abstract [https://ash.confex.com/ash/2014/webprogram/Paper73185.html]**

**FEATURED EXPERTS**

**Dietger Niederwieser, MD**

University of Leipzig

Leipzig, Germany

**SUPPORT STATEMENT**

This educational activity is supported by Millennium: The Takeda Oncology Company; Novartis Oncology; and Onyx Pharmaceuticals, Inc.